Equities

Bio View Ltd

BIOV:TLV

Bio View Ltd

Actions
Health CareMedical Equipment and Services
  • Price (ILa)26.70
  • Today's Change-0.80 / -2.91%
  • Shares traded50.98k
  • 1 Year change-22.38%
  • Beta0.4893
Data delayed at least 20 minutes, as of May 30 2024 15:24 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Bio View Ltd is an Israel-based laboratory equipment developer. The Company manufactures and assembles, markets and services an automated cell diagnostic system for use in cytology, cytogenetic, hematology and pathology laboratories. The workstation is called Duet, which provides automated detection, classification, analysis, and counting of cells for diagnosis and study. Additionally, Duet provides a method to analyze both the morphology and the genetic content of the same cell. The Company has applications in Cancer diagnosis and follow-up of minimal-residual disease (MRD); in pre-natal and post-natal Cytogenetic analyses in the analysis of sperm cells and rare-cell detection (RCD). In 2005, the Company introduced two new scanning workstations: the ALLEGRO, for automated scanning of Fluorescence in-situ Hybridization (FISH) probes without Brightfield scanning, and the ACCORD, for the semi-automated imaging of FISH for breast cancer (Her-2/Neu) and for FISH on tissue.

  • Revenue in ILS (TTM)34.77m
  • Net income in ILS383.00k
  • Incorporated1998
  • Employees--
  • Location
    Bio View Ltd3 Pekeris St.,REHOVOT 7670203IsraelISR
  • Phone+972 89366868
  • Fax+972 89366869
  • Websitehttp://bioview.com
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Polarean Imaging PLC1.27m-53.22m24.58m28.00--0.322--19.41-0.0451-0.04510.00110.03880.01530.11340.19719,568.47-64.22-59.80-72.25-68.3839.6559.23-4,201.18-574.074.66--0.0225---12.86-3.540.7877--30.60--
Telesis Bio Inc91.40m-174.86m25.32m137.00------0.277-28.31-28.3114.8012.940.32313.275.58179,802.90-59.34---67.10--60.43---183.66--3.08-35.890.2015--0.2697---1.14------
Aurora Solar Technologies Inc29.09m-4.70m30.25m----1.88--1.04-0.0098-0.00980.05050.02660.91081.517.98---14.71-82.57-22.77-106.4452.4143.93-16.15-135.081.22-39.660.0665----17.05-5.49--13.30--
Memphasys Ltd116.27k-11.16m30.39m24.00--1.54--261.35-0.0046-0.00460.000050.00590.00330.2732-----31.43-16.26-46.11-19.7344.48---9,600.13-21,518.040.1368-11.780.456---43.39---63.43--8.14--
Precipio Inc58.67m-18.19m31.41m51.00--0.6449--0.5353-3.73-3.7311.608.930.877317.8517.93310,039.20-27.20-44.98-34.82-58.6839.1428.80-31.00-118.070.6201-350.950.0278--61.4639.6252.04--5.37--
Medclair AB14.11m-1.34m33.15m14.00--1.8951.962.35-0.0435-0.04350.51340.60350.63181.394.452,859,714.00-6.00-11.20-7.34-12.9563.1369.51-9.50-26.940.9761-11.650.0053--60.1352.1444.27--24.59--
TOKYO KOKI CO LTD79.38m2.15m34.83m136.0016.200.970912.400.438812.7812.78471.99213.200.94672.654.35--2.560.59054.120.934435.9932.332.710.63641.2517.150.30980.0010.16-8.75112.97-29.83-32.65--
Bio-View Ltd34.77m383.00k36.26m--83.641.2516.471.040.00320.00320.25680.21630.82892.335.48--0.91323.451.234.5761.4858.711.104.202.15--0.1138--19.296.58-34.75--8.77--
Lifeloc Technologies Inc34.58m-90.57k37.88m37.00--1.6846.611.10-0.0099-0.00993.802.481.121.8314.33251,850.30-0.29250.2981-0.33540.340542.2840.75-0.2620.32451.89--0.166--9.992.03145.11-1.09-54.22--
Titan Logix Corp17.57m-1.58m38.07m----0.8348--2.17-0.0204-0.02040.2190.58690.3572.376.94---3.220.6038-3.350.626147.2652.34-9.022.1617.45--0.045--43.576.69-92.63---22.16--
Phoslock Environmental Technologies Ltd7.13m-24.37m38.53m40.00--1.64--5.41-0.0158-0.01580.00460.01530.16132.163.55---55.13---66.97---81.68---341.76--2.82-405.840.051---51.35---184.79------
Scanway SA6.09m-2.74m41.44m59.00--2.82--6.80-2.26-2.265.0112.110.3387.382.93109,601.20-15.21---16.67--46.64---45.01--2.01-220.400.00--153.63---921.77------
Holmarc Opto-Mechatronics Ltd-4.45bn-4.45bn42.63m--------------------------------------------------38.12--129.49------
Data as of May 30 2024. Currency figures normalised to Bio View Ltd's reporting currency: Israeli Shekel ILS

Institutional shareholders

1.16%Per cent of shares held by top holders
HolderShares% Held
Ayalon Financial Solutions (2004) Ltd.as of 28 Dec 20231.29m0.96%
Meitav Mutual Funds Ltd.as of 29 Feb 2024130.91k0.10%
KSM Mutual Funds Ltd.as of 29 Feb 202483.13k0.06%
Migdal Mutual Funds Ltd.as of 29 Feb 202439.71k0.03%
Psagot Mutual Funds Ltd.as of 29 Feb 20249.85k0.01%
Harel Mutual Funds Ltd.as of 29 Feb 20243.38k0.00%
More ▼
Data from 29 Feb 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.